Introduction
About 5% of the population (400,000 in Austria) suffer from neuropathic pain. 50% of them denominate their pain as "very strong". Neuropathic pain patients consult on average 5 different doctors before the main diagnosis is found. The aim of this study was to evaluate the cost-effectiveness of treatment of neuropathic pain with topical Capsaicin Patch 8% versus current standard of care (Pregabalin) in Austria.
Methodology
The analysis was performed using a Decision Tree Model (1 st year) combined with a Markov model adapted for Austria. The model is based on an indirect comparison (C108 CSR, C110 CSR, C116 CSR, C117 CSR Astellas data on file, Sabatowski 2004 , Dworkin et al. 2003 , which results in a conservative estimation, as the efficacy of Capsaicin patch 8% is underestimated due to a large placebo effect. Efficacy assessment was based on the outcome measure QALY. Costs were captured for the year 2011. Resource use was determined by literature research and expert opinion and accurately reflects the Austrian treatment path. The study time horizon was 5 years. There is no significant difference of adverse event probability between the two alternatives; therefore adverse events have not been included. The analysis was performed from the perspective of social health insurance. The analysis was conducted according to Austrian Guidelines for Health Economic Evaluations. The discount rate was 5% for costs and outcomes. The model structure is shown within Fig. 1 .
Resource Use and Cost
Direct costs comprise resource use as a result of treatment or therapy directly attributable to this specific treatment or therapy. Resource use was determined by experts and literature search. Patients receive either Capsaicin 8% patch or Pregabalin. Third line therapy in Austria according to treatment guidelines and expert opinion is duloxetine. Patients suffering from neuropathic pain consult their pain specialist on average 4.5 times per quarter, patients under third line duloxetine therapy additionally 3.6 times. These resource use has been linked to cost parameters. Costs are from Austrian tariff catalogues and official price lists. Medication costs represent social health insurance prices.
Conclusion
Neuropathic pain is a severe condition and leads to an immense deterioration in quality of life of patients. Every person conernced consults on average 5 different specialists before diagnosis. Therapy is manifold and hast to be adapted to every patient individually. In Austria, the treatment of neuropathic pain with Capsaicin Patch 8% is a cost-effective alternative compared to Pregabalin from the perspective of the Austrian social health insurance. 
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The scatter plot shows that most of simulation results are arranged within the upper quadrant on the right hand side. As there is no threshold defined in Austria, most of simulation results are below the fictive willingness to pay threshold of €20,000/QALY. The overall results of the probabilistic as well as the deterministic sensitivity analysis show the robustness of the model and are shown within Fig. 2 .
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Christine Brennig Within a scenario analysis it could be shown that a switch of the base case markov model population treated with Capsaicin 8% patch to the setting of treating only responders (therapy is initiated within hospital outpatient departments) in the ambulant setting leads to the following monetary impact for the Austrian social health insurance (see Table 2 ).
Source: IPF own calculations 
